Home Tags MABs

Tag: mABs

Bi-specific Nanobody Strongly Inhibits Proliferation and Survival of Human Endothelial Cells...

Earlier this week positive in vivo proof-of-mechanism data from the half-life extended bi-specific anti-VEGF/Ang2 Nanobody, was presented at the 8th Euro Global Summit on Cancer Therapy, taking...

The Clinical Landscape of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

Report Presents Latest Development in CMO Market for ADCs

While the basic concept of Antibody-drug Conjugates (ADCs), a new class of biopharmaceutical drugs designed as a targeted therapy, is quite simple - a biological active cytotoxic or chemotherapy drug, is delivered to the target tissue through linking it with a monoclonal antibody - the practical challenge of manufacturing such complex and highly toxic molecules is huge.